BCTG Acquisition Corp. (BCTG) to Combine with Tango Therapeutics in $353M Deal

BCTG Acquisition Corp. (BCTG) to Combine with Tango Therapeutics in $353M Deal

BCTG (NASDAQ:BCTG) has entered into a definitive agreement with biotech firm Tango Therapeutics, bringing total proceeds of $353 million into the deal. Tango is developing a range of cancer therapies designed to suppress tumor growth that are currently in pre-clinical stages. The combined company is expected to trade on the Nasdaq under the symbol “TNGX”
Read More
To access this post, you must purchase a Monthly or Yearly SPACInsider Subscription, or log in if you're a member.